A double-blind crossover study comparing the effects of 5 mg of isosorbide dinitrate given sublingually four times daily for 4 weeks to those of a placebo also administered sublingually four times daily for 4 weeks was performed on 20 male patients with classical exeitional angina pectoris due to coronary artery disease. Isosorbide dinitrate, compared to placebo, significantly reduced the number of anginal episodes requiring nitroglycerin in only one of 17 patients (6%), did not significantly improve exercise tolerance in any of 17 patients, and did not improve the resting or exercise electrocardiograms in any of 17 patients. Isosorbide dinitrate produced headaches in 12 of 19 patients (63%), and two of these patients (11%) were unable to tolerate the drug. Isosorbide dinitrate administered sublingually is no more effective than placebo in treating angina pectoris.
O RAL AND SUBLINGUAL administration of isosorbide dinitrate has been found effective in the reduction of angina pectoris by some investigators.'-6 Sublingual administration of 5 mg of isosorbide dinitrate in patients with angina pectoris has been found to be associated with significant improvement in exercise capacity and in the electrocardiographic response to exercise in tests performed from 5 min to 2 hours after administration of the drug.6 Battock and associates7 found subjective improvement of angina pectoris in five of 10 patients and objective improvement in exercise performance in seven of these 10 patients treated orally with isosorbide dinitrate.
Other investigators found in patients with classical exertional angina pectoris no significant difference in exercise performance whether oral isosorbide dinitrate or placebo was given. 8 The present double-blind crossover study was designed to evaluate the effect of isosorbide dinitrate versus placebo, both administered sublingually, on patients with classical exertional angina pectoris.
Methods
Twenty male patients, 33 to 56 years of age, with angina pectoris for more than 2 years, were subjects in this double-blind crossover study. All patients had five or more episodes of classical exertional angina pectoris due to coronary artery disease per week requiring nitroglycerin. Nineteen of these subjects had a history of one myocardial infarction, each documented by all of the following: a history of prolonged chest pain; elevated serum glutamic oxalacetic transaminase; and evolution of abnormal Q waves on serial electrocardiograms. The 20th patient had an ST-segment depression of 2 mm on exercise electrocardiograms. After the completion of this study, this patient underwent coronary angiography which revealed severe three-vessel disease. Eight of the 20 patients (40%) had diastolic hypertension with diastolic levels above 90 mm of mercury. No tDied. tUnable to tolerate drug. failure or ventricular gallop was present in any patient. None of the patients was given any nitrates except for nitroglycerin in the month prior to the study. Ten patients received sublingual isosorbide dinitrate 5 mg four times daily at 7:30 a.m., 11:30 a.m., 3:30 p.m., and 7:30 p.m. Ten subjects received sublingual placebo four times daily taken at the same times as stated above. The patients received these medications for a 4week period. In the next 4-week study period, the medications were reversed. The medications were prepared and dispensed in a randomized manner by a research pharmacist. The patients took their medications at the times of their exercise studies under the observation of a nurse or one of the authors. The sublingual tablets not used by each patient were returned to us and counted at the end of each study period. Smoking habits and dietary habits did not significantly change in any of the patients during the two study periods.
The number of anginal attacks requiring nitroglycerin during each 4-week study period was recorded. Each patient exercised upright on a bicycle ergometer at a load of 60 watts four times on no medication on the 2 days before starting drug or placebo therapy and four times on the last 2 days of each 4-week study period. Exercise was performed 60 min after medication was adminis-tered. The time in seconds between beginning exercise and the first clinical manifestation of angina was measured. All observations were made by the same investigator. The patients practiced exercising on the bicycle ergometer at a load of 60 watts prior to the control period. Blood pressures were recorded by the same observer with a mercury sphygmomanometer and heart rates with an electrocardiograph at rest and after exercise in all exercise studies. Electrocardiograms using leads II and V6 were taken in the upright position at rest and after exercise in all exercise studies.
Exercise studies were performed in the morning and in the afternoon 4 hours apart on 2 successive days. No patients smoked or took nitroglycerin in the hour prior to exercise. A light breakfast was eaten immediately after the first exercise period, and lunch after the second exercise period.
Results

Side Effects and Complications
Twenty days after beginning placebo therapy, one patient (5%) died at home of a clinical episode suggestive of acute myocardial infarction with cardiac arrest. Two of 19 patients (11%) discontinued taking isosorbide dinitrate because of severe throbbing headaches lasting for 2 to 3 hours after each dose of drug. Twelve of 19 patients (63%) complained of headaches due to isosorbide dinitrate, and in six of 19 patients (32%), the headaches were severe. Transient episodes of dizziness and weakness in two patients, palpitations in one patient, and epigastric distress in one patient were attributed to isosorbide dinitrate.
One patient complained of occasional epigastric distress due to placebo.
After the study was completed, 17 of 19 patients (89%) stated they had taken all of their sublingual tablets as instructed even if side effects had occurred because they had been informed this was an important research study. Counts of the number of tablets not used by each patient also indicated they had taken all their medication. Angina Table 1 reveals the total number of anginal Circulation, Volume XLI, May 1970 episodes requiring nitroglycerin during each 4-week period and the average number per week. Two of 19 patients (11%) were unable to tolerate isosorbide dinitrate. One of 17 patients (6%) had a greater than 50% reduction in anginal episodes requiring nitroglycerin from the drug compared to that from the placebo. One of 17 patients (6%) had a greater than 50% reduction in anginal episodes requiring nitroglycerin from the placebo than that from the drug. Fifteen of 17 patients (88%) had less than 50% reduction in anginal episodes requiring nitroglycerin from the drug than from the placebo. Table 2 indicates the mean exercise performance to the onset of angina while the patient was receiving placebo, isosorbide dinitrate or no medication. The significance of the mean difference in exercise performance was evaluated by computation of tests using the t-test for correlated means. This table reveals that two of 17 patients (12%) had im- proved exercise performance from placebo compared to that from isosorbide dinitrate. Fifteen of 17 patients (88%) had no significant difference in exercise performance from drug versus placebo. Table 3 shows that six of 17 patients (35%) had improved exercise performance on placebo compared to no medication. Two of 17 patients (12%) had better exercise performance on no medication compared to placebo. Nine of 17 patients (53%) had no significant difference in exercise performance on placebo versus no medication. Table 4 presents the group's mean systolic and diastolic blood pressure, heart rate, and product of systolic pressure and heart rate at rest and immediately after exercise on no medication, placebo, and isosorbide dinitrate. There was no significant difference in the group's mean systolic or diastolic blood pressure, heart rate, or product of systolic pressure and heart rate at rest and immediate-ly after exercise during treatment with isosorbide dinitrate versus placebo.
Exercise Performance
Electrocardiograms
There was no difference in the resting or exercise electrocardiograms on no medication, placebo, or isosorbide dinitrate.
Discussion
Only one of 17 patients (6%) had a significant reduction in anginal episodes requiring nitroglycerin during treatment with isosorbide dinitrate compared to placebo, and only one patient (6%) had significantly less angina while receiving the placebo. Fifteen of 17 patients (88%) had no significant difference in exercise performance on drug versus the placebo. Two patients (12%) had significant improvement in exercise performance from placebo over that from the drug, but they had an insignificantly greater number of anginal episodes requiring nitroglycerin during use of the placebo versus the drug. 
